Search

Search Results

• Phase 3 Clinical Trial of 300 mg Vamotinib Directly Compared with High-Dose Imatinib in Chronic Myeloid Leukemia Patients in Chronic Phase with Failure of Standard-Dose Imatinib: Interim Analysis

  A.G. Turkina, O. Yu. Vinogradova, Е.G. Lomaia, B.A. Bakirov, N.M. Kalimulina, T.V. Shelekhova, I.L. Davydkin, T.I. Pospelova, O.A. Shukhov, E.Yu. Chelysheva, V.A. Shuvaev, S. Lavana, V. Khushoo, S. Apte, T.K. Dolai, R.K. Sahoo, Germes Grigorevich Chilov

  1-13

  01.01.2026

• Interim Results of the Russian Prospective Multi-Center Clinical Trial READIT-2020 (Reduction of Tyrosine Kinase Inhibitor Doses in CML Patients, Plasma Imatinib/Nilotinib Concentrations, Sustaining Molecular Response, and Drug Toxicity)

  Margarita Anatolevna Gurianova, V.I. Kazey, O.A. Shukhov, E.Yu. Chelysheva, A.G. Nikiforova, P.D. Sobolev, M.S. Dolov, D.Yu. Grebenkin, A.N. Petrova, A.V. Bykova, I.S. Nemchenko, E.A. Kuzmina, L.V. Gavrilova, A.V. Kokhno, A.G. Turkina

  347-359

  01.10.2024

• Treatment Outcomes with Asciminib, the First Allosteric BCR::ABL1 Tyrosine Kinase Inhibitor, in Chronic Myeloid Leukemia Patients with Multiple Resistance to Prior Therapy

  A.G. Turkina, Elena Andreevna Kuzmina

  311-320

  09.06.2023

• KIR-Genetic Factors and Response to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

  Elena Vital’evna Kuzmich, I.E. Pavlova, L.N. Bubnova, S.S. Bessmeltsev

  119-127

  03.03.2023

• Combination of Ibrutinib and Venetoclax in the Therapy of Chronic Lymphocytic Leukemia: A Review of the Latest Data from Clinical Studies

  A.A. Petrenko, Mariya Igorevna Kislova, E.A. Dmitrieva, E.A. Nikitin, V.V. Ptushkin

  37-45

  01.01.2023

• Gilteritinib as a New Option for the Treatment of Relapsed/Refractory Acute Myeloid Leukemias with FLT3 Gene Mutation: A Literature Review and Three Case Reports

  D.V. Motorin, L.L. Girshova, E.G. Lomaia, Yu.A. Alekseeva, A.V. Petukhov, V.V. Ivanov, E.K. Antonov, S.V. Efremova, A.I. Reshetova, E.N. Tochenaya, Aleksina Alekseevna Shatilova, E.N. Tochenaya, A.V. Petrov, T.S. Nikulina, K.V. Bogdanov, D.V. Ryzhkova, Yu.V. Mirolyubova, I.E. Prokop’ev, I.G. Budaeva

  69-79

  01.01.2023

• Efficacy Predictors of the Third-Line Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase of Chronic Myeloid Leukemia: Results of a Multi-Center Study

  E.G. Lomaia, V.A. Shuvaev, Tamara Vangelevna Chitanava, Yu.D. Matvienko, I.S. Martynkevich, S.V. Voloshin, E.V. Efremova, E.S. Mileeva, M.S. Fominykh, A.E. Kersilova, E.V. Karyagina, N.V. Il’ina, N.V. Dorofeeva, N.V. Medvedeva, A.V. Klimovich, T.V. Shneider, S.A. Stepanova, N.F. Polezhaikovskaya, N.T. Siordiya, E.I. Sbityakova, N.S. Lazorko, E.N. Tochenaya, D.V. Motorin, N.A. Shnalieva, Yu.A. Alekseeva, D.B. Zammoeva, A.Yu. Zaritskey

  271-281

  01.07.2022

• Russian Prospective Non-Randomized Clinical Study on Dose Reduction of Tyrosine Kinase Inhibitors with Subsequent Complete Therapy Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response (READIT-2020): Background, Aim, Mai

  A.G. Turkina, Margarita Anatolevna Gurianova, E.Yu. Chelysheva, O.A. Shukhov

  54-61

  01.01.2022

• Ibrutinib as First-Line Therapy in High-Risk Chronic Lymphocytic Leukemia: Case Reports

  Nadezhda Viktorovna Kurkina, E.A. Repina

  488-495

  01.10.2021

• Opportunities of Chronic Myeloid Leukemia Treatment with Reduced Doses of Tyrosine Kinase Inhibitors

  Margarita Anatolevna Guryanova, E.Yu. Chelysheva, A.G. Turkina

  118-128

  01.01.2021

• Comparative Analysis of Cardiovascular Disorders in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitor Therapy

  L.M. Makeeva, E.I. Emelina, A.V. Bykova, Gennadii Efimovich Gendlin, G.A. Gusarova, I.G. Nikitin, E.Yu. Chelysheva, O.Yu. Vinogradova, I.E. Lazarev, E.G. Arshanskaya, A.G. Turkina

  104-111

  01.01.2020

• Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study “Early Induction Therapy and Monitoring” (РИТМ)

  Oleg Aleksandrovich Shukhov, A.G. Turkina, E.Yu. Chelysheva, A.V. Bykova, A.N. Petrova, G.A. Gusarova, I.S. Nemchenko, A.O. Abdullaev, T.N. Obukhova, A.B. Sudarikov

  194-201

  01.04.2019

• Tyrosine Kinase Inhibitor Resistance in Patients with Chronic Myeloid Leukemia: A 10-Year Study of BCR-ABL Gene Mutation Profile in Russia (2006–2016)

  Vera Vyacheslavovna Tikhonova, M.A. Isakov, V.A. Misyurin, Yu.P. Finashutina, L.A. Kesaeva, N.A. Lyzhko, I.N. Soldatova, N.N. Kasatkina, E.N. Misyurina, A.V. Misyurin

  227-233

  01.07.2018

• PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells

  E.S. Kolotova, V.V. Tatarskii, A.A. Zeifman, O.V. Stroganov, V.S. Stroilov, I.Yu. Titov, F.N. Novikov, A.A. Kalinina, G.G. Chilov, Aleksandr Al’bertovich Shtil’

  1-5

  01.01.2016

• Role of tyrosine-kinase inhibitor selectivity in development of adverse effects during treatment of chronic myeloid leukemia

  A.A. Zeifman, E.Yu. Chelysheva, A.G. Tukrina, G.G. Chilov

  16-27

  01.01.2014